Open original FDA record ↗Recall record
- FDA identifier
- Z-0274-2022
- Company in FDA record
- The Binding Site Group, Ltd.
- FDA record creation date
- Nov 19, 2021
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Due to calibration curves producing a higher activity than routinely expected and that there may be a decrease in separation between calibrator point 5 and calibrator point 6, which can be exacerbated with calibrator 6 activity reaches the optical ceiling of the SPA+ analyzer.
Source facts
- Action
- On 10/15/2021 (revised letter 10/25/2021), the firm sent an "Urgent Medical Device Correction" Notification to customers via email to inform them that it has identified an imprecision at top of calibration curve, where the calibration curves produced using specific lots have a higher activity than routinely expected and that there may be a decrease separation between calibrator point 5 and 6 which can be exacerbated when calibrator 6 activity reaches the optical ceiling of the analyzer and may result in an inaccurate value being reported. Customers are instructed to: Adapt the calibration curve to run as a 5-point curve with immediate effect as below 1. Stop using the 6-point calibration curve for the affected kit lots. 2. Run a 5-point calibration curve by entering values for Calibrator 1 to Calibrator 5 only as found on the Quality Control Certificate provided within the kit in ascending order on Page 1 of the Item parameters. Leave Standard 6 blank. Ensure the Auto Fill button is pressed after entering the value for Calibrator 5 on page 1. The analyser will automatically calculate and enter the revised measuring ranges on Item pages 3 and 4. 3. View Item parameter pages 3 and 4 to ensure correct value entry. 4. Before requesting calibration, view the CALIB screen and delete any existing rack position and OD information shown for STD-6 of the corresponding assay. 5. Calibration curves must only be accepted if Absorbance values increase with increasing concentration as stated in Section D.2.2 of the SPAPLUS Reference Guide (FIN012). -The expiry of the above kit lots has been reduced from 31/OCT/2022 to 30/APR/2022. Update records accordingly as the affected kit lots must not be used beyond this point. 6. Fill out and return the TSWS18 E-Back form to Technical.support@bindingsite.com or to your local The Binding Site Representative within two weeks of receiving this notification. For question/further information, contact Local Binding Site Representative or Techn
- Initiated
- 2021-10-15
- Root cause
- Nonconforming Material/Component
- Terminated
- 2025-02-04
- Distribution
- U.S.: CA, CO, FL, IL, IN, KY, LA, MI, NY, OK, SD, TX and VA. O.U.S.: Canada
- Recall number
- Z-0274-2022
- Recall status
- Terminated
- CDRH record ID
- 190021
- FDA record created
- 2021-11-19
- Recall event number
- 88921